Meril launches Myval Transcatheter Aortic Valve Replacement therapy

TAVR is an established treatment modality for patients who are at a high risk or unwilling to undergo open heart valve replacement surgery

Meril Life Sciences has introduced the first ever indigenously designed and manufactured Transcatheter Aortic Heart Valve (TAVR) – Myval. With this launch, Meril, a global medical devices company becomes the First Indian Company to make TAVR therapy commercially available on the world stage. TAVR is an established treatment modality for patients who are at a high risk or unwilling to undergo open heart valve replacement surgery. TAVR is a minimally invasive procedure in which the doctor places a replacement valve into the patient’s native diseased valve via a catheter inserted through the femoral artery (large artery in groin). This is an alternative way to replace diseased valves without undergoing traditional open heart procedure.